论文部分内容阅读
目的:探讨顺铂(DDP)为基础的联合化疗在非小细胞性肺癌(NSCLC)治疗中对血糖变化的影响。方法:以顺铂为基础的联合化疗患者150例,回顾性分析化疗前后的血糖变化情况及相关临床资料。结果:150例患者中,化疗期间6例(4.00%)确诊为糖尿病(DM),6例(4.00%)出现糖耐量减低(IGT),10例(6.67%)出现空腹血糖受损(IFG),8例(5.33%)一过性血糖升高,继发DM患者化疗前后的平均血糖值分别为(5.08±0.18)和(10.79±2.80)mmol/L,化疗前后空腹血糖水平差异有统计学意义,t=5.200,P=0.003。继发DM多发生在化疗的第3.5个周期,DDP的累积量约280mg/m2。结论:常规剂量顺铂化疗能引起DM、IGT、IFG及一过性血糖升高,化疗期间应密切监测血糖。
Objective: To investigate the effect of cisplatin (DDP) -based combination chemotherapy on blood glucose in the treatment of non-small cell lung cancer (NSCLC). Methods: 150 cases of cisplatin-based combination chemotherapy patients, retrospective analysis of changes in blood glucose before and after chemotherapy and related clinical data. Results: Among the 150 patients, 6 cases (4.00%) were diagnosed with diabetes mellitus (DM), 6 cases (4.00%) had IGT, and 10 cases (6.67%) had impaired fasting glucose (IFG) , 8 cases (5.33%) transient elevated blood glucose, the mean blood glucose before and after chemotherapy in patients with secondary DM were (5.08 ± 0.18) and (10.79 ± 2.80) mmol / L, respectively, before and after chemotherapy fasting blood glucose levels were statistically significant Meaning, t = 5.200, P = 0.003. Secondary DM occurred in the first 3.5 cycles of chemotherapy, DDP cumulative amount of about 280mg / m2. CONCLUSIONS: Conventional doses of cisplatin chemotherapy can cause elevated levels of DM, IGT, IFG and transient glucose, and should be closely monitored during chemotherapy.